NCT01587755

Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP)

Optimising Outpatient Care in Mild to Moderate Psoriasis by a Newly Developed 'Topical Treatment Optimising Programme' - an International Study Using Daivobet®/Dovobet® Gel

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,852 (actual)
• Sponsor: Kristian Reich, MD · Individual
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Topical Treatment Optimisation Programme (TTOP) has been developed by the sponsor together with Patient Boards and an Expert Advisory Board to overcome non-adherence problems.

Detailed description

A Topical Treatment Optimisation Programme (TTOP) has been developed by the sponsor together with Patient Boards and an Expert Advisory Board. This tool is created to address patients' non-adherence in topical therapy and the resulting underperformance of such treatments in controlling psoriatic disease. The study addresses the effect of the relationship between the patient and the health care professional, one of the important factors that can affect treatment adherence and therapeutic efficacy. The TTOP will be compared to standardised regular care (called 'non-TTOP'). It is intended to clinically show the importance of an optimised contact between the patient and health care professional.

Conditions

• Mild to Moderate Psoriasis

Interventions

Type	Name	Description
OTHER	TTOP	Patient is taken care of in an intensified, optimised manner
OTHER	non-TTOP	Standard medical care

Timeline

• Start date: 2012-03-01
• Primary completion: 2014-06-01
• Completion: 2014-06-01
• First posted: 2012-04-30
• Last updated: 2015-03-09

Locations

93 sites across 8 countries: Denmark, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom